Brief: Crescent Biopharma Inc Q2 EPS $-4.93
31/07/2025 13:35
July 31 (Reuters) - Crescent Biopharma Inc CBIO.O: CRESCENT BIOPHARMA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS CRESCENT BIOPHARMA INC: Q2 EPS $-4.93 Source text: ID:nGNX8f4tCn Further company coverage: CBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering